Premaitha Health

Premaitha Health is an innovative molecular diagnostics company bringing advantages in Next Generation DNA sequencing to non-invasive prenatal testing (NIPT). Premaitha’s flagship product, the IONA® test is the first non-invasive in vitro diagnostic product for prenatal screening, enabling clinical laboratories to offer CE-marked NIPT in-house for the first time. The IONA® test estimates the risk of the fetus having Trisomy 21 (Down’s syndrome), Trisomy 18 (Edwards’ syndrome) and Trisomy 13 (Patau’s syndrome). The IONA® test is a complete diagnostic system that is simple and standardised, enabling Premaitha’s clinical laboratory customers to perform the test in their laboratory, using existing clinical workflow. The IONA® test has a higher detection rate and lower false positive rate giving pregnant women, their families and their doctors’ greater confidence in the result thereby reducing the need for unnecessary invasive follow-up tests and the associated anxiety and stress. Premaitha’s strategy aims to accelerate the broad dissemination of advanced NIPT tests to benefit more laboratories, doctors and pregnant women.
Premaitha is listed on the London Stock Exchange’s Alternative Investment Market (AIM). Its R&D, manufacturing and commercial operation is located on the Manchester Science Park, UK.

Type
Public
HQ
Manchester, GB
Founded
2013
Size (employees)
43 (est)
Premaitha Health was founded in 2013 and is headquartered in Manchester, GB

Premaitha Health Office Locations

Premaitha Health has office in Manchester
Manchester, GB

Premaitha Health Metrics

Premaitha Health Summary

Market capitalization

£24.6 m

Closing share price

£0.1
Premaitha Health's current market capitalization is £24.6 m.

Premaitha Health Financials

Premaitha Health's revenue is £2.5 m in FY, 2016 which is a 1754.1% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

£257.7 k£102.5 k£132.3 k£2.5 m

Revenue growth, %

(60.2%)29%1754.1%

Cost of sales

£555.2 k£1.8 m

Gross profit

(£297.5 k)£701 k

Gross profit Margin, %

(115.4%)28.6%

Operating expense total

£4.7 m£12.7 m

Premaitha Health Market Value History

We estimate that Premaitha Health's current employees are approximately 32% female and 68% male.

Premaitha Health Online Presence

Premaitha Health News

Premaitha Health Company Life

You may also be interested in